“Other companies come to us and want CDMO work in the biosimilar space because we know what we’re doing, but our goal is not to become 100% biosimilars. Our goal is to become a leading biologics manufacturer and biosimilars are a part of what we do,” said our Vice President of Strategy, Programs and Portfolio – Alexandra Moulson in an interview with The Center for Biosimilars®.
Read the full interview and find out more about Polpharma Biologics CDMO services, forward expansion and whether COVID-19 had an impact on the company in recent months.
Alexandra Moulson
Vice President of Strategy, Programs and Portfolio at Polpharma Biologics
